Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
Open Access
- 29 December 2022
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (1)
Abstract
Background: The accuracy of alpha‐fetoprotein (AFP) as a diagnostic marker for hepatocellular carcinoma (HCC) is insufficient, and the application of abnormal prothrombin (PIVKA‐II) in HCC is still controversial.Methods: Serum AFP and PIVKA‐II levels were analyzed in 145 cases of HCC, 57 of benign liver disease, 55 of cholangiocarcinoma and gallbladder carcinoma, 112 of other gastrointestinal tumors with liver metastasis, and 101 healthy controls. Receiver operating characteristic curve and area under the curve were used to evaluate the diagnostic value of AFP and PIVKA‐II for HCC. The changes in serum AFP and PIVKA‐II levels before and after treatment in 47 HCC patients who underwent surgery and 77 who received interventional treatment were used to evaluate treatment efficacy and prognosis in HCC.Results: The concentrations of AFP and PIVKA‐II in the HCC group were significantly higher than those in other groups (p < 0.01). The diagnostic value of PIVKA‐II in HCC was better than that of AFP, and combined detection improved the diagnostic sensitivity and specificity. The levels of AFP and PIVKA‐II after liver cancer surgery were significantly lower than those before surgery. Elevated levels of PIVKA‐II before surgery predicted disease progression, and patients who remained positive for PIVKA‐II after surgery had worse prognosis than those who became negative after surgery.Conclusions: Combined detection of AFP and PIVKA‐II is superior to both tests alone. We found that higher serum level of PIVKA‐II indicates more severe HCC, with worse prognosis, while the level of AFP had no correlation with the prognosis.Keywords
This publication has 31 references indexed in Scilit:
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated VersionDigestive Diseases, 2011
- Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombinLiver International, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Protein induced by vitamin K absence or antagonist II-producing gastric cancerWorld Journal of Gastrointestinal Pathophysiology, 2010
- Serological markers of liver cancerBest Practice & Research Clinical Gastroenterology, 2005
- Hepatocellular carcinoma in cirrhosis: Incidence and risk factorsGastroenterology, 2004
- PIVKA-II-producing advanced gastric cancerInternational Journal of Clinical Oncology, 2004
- Randomized controlled trial of screening for hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2004
- The role of des-γ-carboxy prothrombin levels in hepatocellular carcinoma and liver tissuesCancer Letters, 2000